Novel Coronavirus disease (COVID-19): physiology to pathophysiology and therapeutics including herbal medicines
https://doi.org/10.4081/idhm.2023.313
Accepted: 4 May 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
COVID-19 emerged as a public health emergency of international concern in 2019 and spread globally. The spectrum of the diseases varied from asymptomatic to severe, even resulting in mortality. Gender and pre-existing co-morbidities were identifiable risk factors. Diabetes, hypertension, and chronic respiratory and cardiovascular diseases pose a risk of severe infections and manifestations. The vulnerability was due to ACE 2 receptors, thereby enhancing the entry and subsequent multiplication of the virus. Immune responses acted as the two-way sword, with cytokine storms posing a risk of severe complications. COVID-19 is also associated with long-term effects varying from neuropsychiatric to other complications. Mutations are expected to pose a challenge in the future. The second wave was also related to fungal infections due to varied causes like side effects of treatment and opportunistic infection due to immune suppression from using steroids. Naturopathy is also expected to work wonders. However, scientific and evidence-based results are required. COVID combat requires a multi-level approach. Nutrition and strict adherence to health and hygiene are essential preventive strategies.
Liu C, Zhou Q, Li Y, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. 2020;6:315-31. DOI: https://doi.org/10.1021/acscentsci.0c00272
Patel J, Parikh S, Patel R, et al. Role of Secondary Attack Rate in The Surge of COVID-19 Cases: A Comparative Retrospective Cohort Study between First Wave and Second Wave of COVID-19: Role of Secondary Attack Rate in The Surge of COVID-19 Cases. The Journal of Pharmaceutical Sciences and Medicinal Research. 2021;1:45–57. DOI: https://doi.org/10.2139/ssrn.3905511
Choudhary OP, Priyanka, Singh I, Rodriguez-Morales AJ. Second wave of COVID-19 in India: Dissection of the causes and lessons. Travel Med Infect Dis. 2021;43:102126. DOI: https://doi.org/10.1016/j.tmaid.2021.102126
Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls [Internet]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/.
Swarna A . Mini Review -New emerging COVID Strain. J Intensive & Crit Care. 2020;6:25.
Li X, Geng M, Reng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10:102-8. DOI: https://doi.org/10.1016/j.jpha.2020.03.001
Prompetchara E, Ketloy C Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asia Pacific Journal of Allergy and Immunology. 2020;38:1-9.
Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International Journal of OralScience.2020;12. DOI: https://doi.org/10.1038/s41368-020-0074-x
Wang J, Zhao S, Liu M, et al. ACE2 expression by colonic epithelial cells is associated with viral infection, immunity, and energy metabolism. Available from: https://www.medrxiv.org/content/10.1101/2020.02.05.20020545v1.full.pdf.
Guo Y, Cao Q, Hong Z, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Military Med Re. 2020;7:11. DOI: https://doi.org/10.1186/s40779-020-00240-0
Glowacka I, Bertram S, Herzog P, et al. Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63. Journal of Virology. 2009;84:1198-205. DOI: https://doi.org/10.1128/JVI.01248-09
Gu J, Korteweg K. Pathology and Pathogenesis of Severe Acute Respiratory Syndrome. The American Journal of Pathology. 2007;170:1136-47. DOI: https://doi.org/10.2353/ajpath.2007.061088
Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med 2020;383:1724-34. DOI: https://doi.org/10.1056/NEJMoa2026116
Tetro JA. Is COVID-19 receiving ADE from other corona viruses? Microbes and Infections. 2020;22:72-3. DOI: https://doi.org/10.1016/j.micinf.2020.02.006
Wan Y, Shang J, Sun S, et al. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. Journal of Virology. 2020;94:e02015-19. DOI: https://doi.org/10.1128/JVI.02015-19
Winarski KL, Tang J, Klenow L, et al. Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics. Proceedings of the National Academy of Sciences. 2019;116:15194-9. DOI: https://doi.org/10.1073/pnas.1821317116
Thomas S, Redfern JB, Lidbury BA, Suresh M. Antibody-dependent enhancement and vaccine development. Expert Review of Vaccines. 2016;5,409-12. DOI: https://doi.org/10.1586/14760584.5.4.409
Prohaszka Z, Toth FD, Banhegyi D, Fust G. Complement-Mediated Antibody-Dependent Enhancement of Viral Infections. Available from: https://doi.org/10.1007/1-4020-8056-5_12. DOI: https://doi.org/10.1007/1-4020-8056-5_12
Florinda HD, Kleiner R, Vaskovich Koubi D, et al. Immune-mediated approaches against COVID-19. Nat Nanotechnol. 2020;15:630-45. DOI: https://doi.org/10.1038/s41565-020-0732-3
Phimister EG, Mantovani A, Netea MC. Trained innate immunity, epigenetics, and COVID-19. New Eng J of Medicine. 2020;383:1078-80. DOI: https://doi.org/10.1056/NEJMcibr2011679
Deng S, Peng H. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J. Clin. Med. 2020;9:575. DOI: https://doi.org/10.3390/jcm9020575
Abdallah H, Porterfield F, Fajgenbaum D. Symptomatic relapse and long term sequelae of COVID-19 in a previously healthy 30-year-old man. BMJ Case Rep. 2020;13:e:239825. DOI: https://doi.org/10.1136/bcr-2020-239825
Angeletti S, Benvenuto D, Bianchi M, et al. COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. J Med Virol. 2020;92:584-8. DOI: https://doi.org/10.1002/jmv.25719
Banoun H. Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System. Nephron. 2021;145:392-403. DOI: https://doi.org/10.1159/000515417
Yuen KS, Ye ZW, Fung SY, et al. SARS-CoV-2 and COVID-19: The most important research questions. Cell & Bioscience.2020;10. DOI: https://doi.org/10.1186/s13578-020-00404-4
Bunders MJ, Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity. 2020;53:487-95. DOI: https://doi.org/10.1016/j.immuni.2020.08.003
Baiardo RM, Landoni G, Di Napoli D, et al. Novel Coronavirus disease (COVID-19) in Italian Patients: Gender differences in presentation and severity. Saudi J Med Med Sci. 2021;9:59-62. DOI: https://doi.org/10.4103/sjmms.sjmms_542_20
Pradhan A, Qlsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differer. 2020;11:53. DOI: https://doi.org/10.1186/s13293-020-00330-7
Viveiros A, Rasmuson R, Vu J, et al. Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex Hormones. Am J Physiol Heart Circ Physiol. 2021;320:H296–304. DOI: https://doi.org/10.1152/ajpheart.00755.2020
Tadiri CP, Gisinger T, Kautzky-Willer A, et al. CMAJ 2020 September 8;192:E1041-5. DOI: https://doi.org/10.1503/cmaj.200971
Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020;46:846-8. DOI: https://doi.org/10.1007/s00134-020-05991-x
Husaini SHM, Abqari S, Siddiqui OA, et al. Clinico-epidemiological Profile and Outcomes of COVID-19 Patients Admitted in Jawaharlal Nehru Medical College and Hospital: A Retrospective Study. JCDR. 2021;15:OC22-6. DOI: https://doi.org/10.7860/JCDR/2021/50659.15210
Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance : a prospective observational study from the ZOE COVID study. The Lancet. 2022;399:1618-24. DOI: https://doi.org/10.1016/S0140-6736(22)00327-0
Copur S, Berkkan M, Basile C, et al. Post-acute COVID-19 syndrome and kidney diseases: what do we know? J Nephrol .2022;35:795–805. DOI: https://doi.org/10.1007/s40620-022-01296-y
Spudich S, Nath A. Nervous System consequences of COVID-19. Science. 2022;375:267-9. DOI: https://doi.org/10.1126/science.abm2052
Leung EH, Fan J, Flynn Jr HW, Albini TA. Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare. Clin Ophthalmol. 2022;16:1-13. DOI: https://doi.org/10.2147/OPTH.S336963
Waseem SMA, Mehdi SH, Abidi AJ. Impact of COVID-19 pandemic on non-communicable chronic lifestyle diseases in population of India: A systematic review. Natl J Physiol Pharm Pharmacol 2023;13. DOI: https://doi.org/10.5455/njppp.2023.13.11403202108092022
D’Ippolito S, Turchiano F, Vitagliano A, et al. Is There a Role for SARS-CoV-2/COVID-19 on the Female Reproductive System? Frontiers in Physiology. 2022;13:845156. DOI: https://doi.org/10.3389/fphys.2022.845156
Tian YU, Zhou L. Evaluating the impact of COVID-19 on male reproduction. Reproduction. 2021;161:R37-44. DOI: https://doi.org/10.1530/REP-20-0523
Veronesi F, Contartese D, Martini L, et al. Speculation on the pathophysiology of musculoskeletal injury with COVID-19 infection. Front Med (Lausanne). 2022;14:930789. DOI: https://doi.org/10.3389/fmed.2022.930789
Ali M, Bonna AS, Sarkar AS, Islam A. Is Coronavirus Infection Associated With Musculoskeletal Health Complaints? Results From a Comprehensive Case-Control Study. J Prim Care Community Health. 2022;13:21501319221114259. DOI: https://doi.org/10.1177/21501319221114259
Hasan LK, Deadwiler B, Haratian A, et al. Effects of COVID-19 on the Musculoskeletal System: Clinician’s Guide. Orthop Res Rev. 2021;13:141-50. DOI: https://doi.org/10.2147/ORR.S321884
Lavery AM, Preston LE, Ko JY, et al. Characteristics of Hospitalized COVID-19 Patients Discharged and Experiencing Same-Hospital Readmission — United States, March–August 2020 Morbidity and Mortality Weekly Report. 2020;69:1695-9. DOI: https://doi.org/10.15585/mmwr.mm6945e2
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395:1054-62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3
World Health Organization. Tuberculosis and COVID-19. Available from: https://www.who.int/tb/COVID_19considerations_tuberculosis_services.pdf
Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Internal Medicine. JAMA Intern Med. 2020;180:934-43. DOI: https://doi.org/10.1001/jamainternmed.2020.0994
Pal R, Banerjee M. COVID‑19 and the endocrine system: exploring the unexplored. Journal of Endocrinological Investigation . 2020; 43: 1027–1031 https://doi.org/10.1007/s40618-020-01276-8. DOI: https://doi.org/10.1007/s40618-020-01276-8
Marazuela M, Giustina A, Domingo MP. Endocrine and metabolic aspects of the COVID-19 pandemic. Reviews in Endocrine and Metabolic Disorders. 2020;21:495–507. DOI: https://doi.org/10.1007/s11154-020-09569-2
Nigro E, Perrotta F, Polito R, et al. Metabolic Perturbations and Severe COVID-19 Disease:Implication of Molecular Pathways. International Journal of Endocrinology. 2020;2020:8896536. DOI: https://doi.org/10.1155/2020/8896536
Covi Diab Registry. Available from: http://covidiab.e-dendrite.com
Liu T, Zhang J, Yang Y, et al. The potential role of IL-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 2020;12:e12421. DOI: https://doi.org/10.15252/emmm.202012421
Kim ES, Choe PG, Park WB, et al. Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection. J Korean Med Sci. 2016; 31:1717–25. DOI: https://doi.org/10.3346/jkms.2016.31.11.1717
Kim SM, Kim YG, Kim DJ, et al. Inflammasome-Independent Role of NLRP3 Mediates Mitochondrial Regulation in Renal Injury. Front. Immunol.2018; 9:2563. DOI: https://doi.org/10.3389/fimmu.2018.02563
Zhao C, Zhao W. NLRP3 Inflammasome—A Key Player in Antiviral Responses. Front. Immunol. 2020;11:211. DOI: https://doi.org/10.3389/fimmu.2020.00211
Xie J, Li Y, Shen X, et al. Dampened STING-Dependent Interferon Activation in Bats. Cell Host & Microbe.2018;23:297–301. DOI: https://doi.org/10.1016/j.chom.2018.01.006
D'Elia RV, Harrison K, Oyston PC, et al. Clark. Targeting the “Cytokine Storm” for Therapeutic Benefit. Clinical and Vaccine Immunology. 2013;20:319-27. DOI: https://doi.org/10.1128/CVI.00636-12
Tisoncik JR, Korth MJ, Simmons CP, et al. Into the eye of the cytokine storm. MicrobiolMolBiol Rev. 2012;76:16–32. DOI: https://doi.org/10.1128/MMBR.05015-11
Kikkert M. Innate Immune Evasion by Human Respiratory RNA Viruses. Journal of Innate Immunity.2020;12:4-20. DOI: https://doi.org/10.1159/000503030
Behrens EM, Koretzky GA. Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era. Arthritis & Rheumatology. 2017;69:1135-43. DOI: https://doi.org/10.1002/art.40071
Mehat P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-4. DOI: https://doi.org/10.1016/S0140-6736(20)30628-0
Liu Q, Zhou Y, Yang Z. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell MolImmunol .2016;13:3–10. DOI: https://doi.org/10.1038/cmi.2015.74
Qu R, Ling Y, Zhang YH, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020;92:1533-41. DOI: https://doi.org/10.1002/jmv.25767
Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27:89-95. DOI: https://doi.org/10.1016/j.cmi.2020.09.023
Steardo Jr. L, Steardo L and Verkhratsky A. Psychiatric face of COVID-19. Translational Psychiatry. 2020;10:261. DOI: https://doi.org/10.1038/s41398-020-00949-5
Pantelis C, Jayaram M, Hannan AJ, et al. Neurological, neuropsychiatric, and neurodevelopmental complications of COVID-19. Australian & New Zealand Journal of Psychiatry.2021;55:750-62. DOI: https://doi.org/10.1177/0004867420961472
Wang F, Kream RM, Stefano GB. Long-Term Respiratory and Neurological Sequelae of COVID-19. Med Sci Monit, 2020;26:e928996. DOI: https://doi.org/10.12659/MSM.928996
Butler M, Pollak TA, Rooney AG, Michael BD, and Nicholson TR. Neuropsychiatric complications of covid-19. BMJ 2020;371:m3871 DOI: https://doi.org/10.1136/bmj.m3871
Guler SA, Ebner L, Beigelman C, et al . Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021;57:2003690. DOI: https://doi.org/10.1183/13993003.03690-2020
John AE, Joseph C, Jenkins G, Tatler AL. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunol Rev. 2021;302:228-240. DOI: https://doi.org/10.1111/imr.12977
Maucourant C, Filipovic I, Ponzetta A, et al. Karolinska COVID-19 Study Group. Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol 2020;5:eabd6832. DOI: https://doi.org/10.1126/sciimmunol.abd6832
Rolfe RJ , Smith CM, Wolfe CR. The Emerging Chronic Sequelae of COVID-19 and Implications for North Carolina. N C Med J. 2021;82:75-8. DOI: https://doi.org/10.18043/ncm.82.1.75
Demertzis ZD, Dagher C, Malette KM, et al. Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): a clinical case series. European Heart Journal - Case Reports. 2020;4:1-6. DOI: https://doi.org/10.1093/ehjcr/ytaa179
Ladinska EBM, Kronenberg G. Psychological and neuropsychiatric implications of COVID‑19. Eur Arch Psychiatry Clin Neurosci. 2021;271:235-48. DOI: https://doi.org/10.1007/s00406-020-01210-2
Becker RC. COVID‑19 and its sequelae: a platform for optimal patient care,discovery and training. Journal of Thrombosis and Thrombolysis. 2021;51:587–94. DOI: https://doi.org/10.1007/s11239-021-02375-w
Vishal Rao US, Arakeri G, Kaler AK, et al. Rapid Response: Mucormycosis in COVID-19 2nd wave: hypoxia as key trigger and the biological impact of health policies. BMJ 2021;373:n1238.
Kumar M, Sarma DK, Shubham S, et al. Mucormycosis in COVID-19 pandemic: Risk factors and linkages. Curr Res Microb Sci. 2021;2:100057. DOI: https://doi.org/10.1016/j.crmicr.2021.100057
Meawed TE, Ahmed SM, Mowafy SMS, et al. Bacterial and fungal ventilator-associated pneumonia in critically ill COVID-19 patients during the second wave. J Infect Public Health. 2021;14:1375-80. DOI: https://doi.org/10.1016/j.jiph.2021.08.003
Li Y, Shi K, Qi F, et al.Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study. International Journal of Infectious Diseases.2021;103:507-13. DOI: https://doi.org/10.1016/j.ijid.2020.12.023
Jamshed H, Fatima Z, Din IU, et al. Diagnostic and Treatment startegie for COVID-19. AAPS Pharm Sci Tech. 2020;21:222. DOI: https://doi.org/10.1208/s12249-020-01756-3
Magro G. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Res. 2020;286:198070. DOI: https://doi.org/10.1016/j.virusres.2020.198070
Pang J, Xu F, Aondio G, et al. Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat Commun. 2021;12:814. DOI: https://doi.org/10.1038/s41467-021-21085-8
Pitt B, Sutton NR, Wang Z, et al. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. European Journal of Pharmacology. 2021;898:173988. DOI: https://doi.org/10.1016/j.ejphar.2021.173988
Zhong J, Tang J, Ye C, Dong L. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol 2020;2:e428–36. DOI: https://doi.org/10.1016/S2665-9913(20)30120-X
Qayyumi B, Sharin F, Singh A, et al. Management of COVID-19: A brief overview of the various treatment strategies. Cancer Research Stat Treat. 2020;3:233-43. DOI: https://doi.org/10.4103/CRST.CRST_187_20
da Silva KN, Gobatto ALN, Costa-Ferro ZSM et al. Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19? Stem Cell Res Ther. 2021;12:425. DOI: https://doi.org/10.1186/s13287-021-02502-7
Vlachou M, Siamidi A, Dedeloudi A, et al. Pineal hormone melatonin as an adjuvant treatment for COVID-19 (Review). Int J Mol Med .2021;47:47. DOI: https://doi.org/10.3892/ijmm.2021.4880
Zuo Y, Warnock M, Harbaugh A, et al. Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients. Sci Rep. 2021;11:1580. DOI: https://doi.org/10.1038/s41598-020-80010-z
Rahman MM, Fatema K, Uzzaman A, et al. A Comprehensive Study of Artificial Intelligence and Machine Learning Approaches in Confronting the Coronavirus (COVID-19) Pandemic. Int J Health Serv. 2021;51:446-61. DOI: https://doi.org/10.1177/00207314211017469
Weiss C, Carriere M, Fusco L, et al. Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic. ACS Nano 2020;14:6383−406. DOI: https://doi.org/10.1021/acsnano.0c03697
Ye Q, Wang B, Zhang T, et al. The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19. Am J Physiol Gastrointest Liver Physiol. 2020;319:G245-52. DOI: https://doi.org/10.1152/ajpgi.00148.2020
Sundararaman A, Ray M, Ravindra PV, Halami PM. Role of probiotics to combat viral infections with emphasis on COVID-19. Appl Microbiol Biotechnol. 2020;104:8089-104. DOI: https://doi.org/10.1007/s00253-020-10832-4
Zheng D, Liwinski T, Elina E. Interaction between microbiota and immunity in health and Disease. Cell Research. 2020;30:492–506; DOI: https://doi.org/10.1038/s41422-020-0332-7
Rishi P, Thakur K, Shania V, et al. Diet, Gut Microbiota and COVID-19. Indian J Microbiol. 2020;60:420-9. DOI: https://doi.org/10.1007/s12088-020-00908-0
Mohammed S. Razzaque. COVID-19 pandemic: Can zinc supplementation provide an additional shield against the infection? Computational and Structural Biotechnology Journal. 2021;19:1371-8. DOI: https://doi.org/10.1016/j.csbj.2021.02.015
Chowdhury MA, Hossain N, Kashem MA, et al. Immune Response in COVID-19: A Review. J Infect Public Health. 2020;13:1619-29. DOI: https://doi.org/10.1016/j.jiph.2020.07.001
Aman F, Masood S. How Nutrition can help to fight against COVID-19 Pandemic. PJMS. 2020;36:S121-3. DOI: https://doi.org/10.12669/pjms.36.COVID19-S4.2776
Goyal A, Ojeda EFC, Schiffer JT. Potency and timing of antiviral therapy as determinants of duration of SARS-COV-2 shedding and intensity of inflammatory response. Sci Adv. 2020;6:eabc7112. DOI: https://doi.org/10.1126/sciadv.abc7112
Varghese GM, John R, Manesh A, et al. Clinical management of COVID-19. Indian J Med Research. 2020;151:401-10. DOI: https://doi.org/10.4103/ijmr.IJMR_957_20
Sun Z, He G, Huang N, et al. Glycyrrhizic Acid: A Natural Plant Ingredient as a Drug Candidate to Treat COVID-19. Front. Pharmacol. 2021;12:707205. DOI: https://doi.org/10.3389/fphar.2021.707205
Nagoor Meeran MF, Javed H, Sharma C, Goyal SN, et al. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. Heliyon. 2021;7:e05990. DOI: https://doi.org/10.1016/j.heliyon.2021.e05990
Nugraha RV, Ridwansyah H, Ghozali M, et al. Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons. Evid Based Complement Alternat Med. 2020;2020:2560645. DOI: https://doi.org/10.1155/2020/2560645
Khanna K, Kohli SK, Kaur R, et al. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle. Phytomedicine. 2021;85:153361. DOI: https://doi.org/10.1016/j.phymed.2020.153361
Saba F, Zainab N. Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID‑2019). Chemistry Afric. 2021;4:1–13. DOI: https://doi.org/10.1007/s42250-020-00203-x
Elfiky AA. Natural products may interfere with SARS-CoV-2 attachment to the host cell. Journal of biomolecular structure & dynamic. 2021;39:3194-203. DOI: https://doi.org/10.21203/rs.3.rs-22458/v1
Verma S, Twilley D, Esmear T, et al. Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19). Frontiers in Pharmacology. 2020;11:561334. DOI: https://doi.org/10.3389/fphar.2020.561334
Praditya D, Kirchhoff L, Brüning J, et al. Anti-infective Properties of the Golden Spice Curcumin. Front Microbiol. 2019;10:912. DOI: https://doi.org/10.3389/fmicb.2019.00912
Ahmad S, Zahiruddin S, Parveen B, et al. Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research. Frontiers in Pharmacology. 2021;11:578970. DOI: https://doi.org/10.3389/fphar.2020.578970
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
